Welcome to our dedicated page for GoodRx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. filings document the financial reporting, governance, and public-company controls of a Nasdaq-listed digital healthcare platform for prescription savings. Its 8-K reports furnish quarterly operating results, revenue categories such as prescription transactions, subscriptions, and Pharma Direct, non-GAAP financial measures, and business outlook disclosures tied to medication access and pharmacy-market conditions.
GoodRx regulatory filings also cover proxy governance, board classification matters, director departures, officer appointments and resignations, executive compensation, equity awards under the 2020 Incentive Award Plan, and changes in the company’s independent registered public accounting firm.
GoodRx Holdings reported Q2 2026 revenue of $200.4 million, down 1% from $203.1 million a year earlier, as its business mix shifted. Prescription transactions revenue fell 26% to $106.4 million on fewer Monthly Active Consumers, broader retail pharmacy changes, lower unit economics and a deliberate pivot of product and marketing spend toward newer subscription offerings.
Subscription revenue rose 39% to $28.5 million and Pharma Direct revenue increased 76% to $61.6 million, helped by condition‑specific subscriptions, including weight loss, and GLP‑1 access programs. Net income was $8.5 million versus $12.8 million, with Adjusted EBITDA of $63.7 million and a 31.8% margin. Operating cash flow strengthened to $80.8 million. As of June 30, 2026, cash and cash equivalents were $296.1 million and total debt $492.5 million. Monthly Active Consumers averaged 5.0 million, while subscription plans grew to 764,000. Management raised full‑year 2026 guidance to revenue of $790–$805 million, a (1%) to 1% year‑over‑year change versus 2025 revenue of $796.9 million, and Adjusted EBITDA of $240–$250 million.
GoodRx Holdings officer Christopher A. McGinnis exercised 36,988 restricted stock units into Class A common stock, with each unit representing a contingent right to receive one share. To satisfy tax obligations, 16,294 shares were withheld at $3.01 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, he held 198,310 Class A shares directly and 369,877 restricted stock units that, under the award terms, vest in 12 equal quarterly installments beginning April 15, 2026, subject to continued service.
GoodRx Holdings director and officer Wendy Lynn Barnes converted 277,288 restricted stock units into Class A common stock on July 15, 2026. To cover tax liabilities, 120,456 shares were delivered at $3.01 per share rather than sold in open-market trades.
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan reported equity compensation activity involving Class A Common Stock and restricted stock units. On July 15, 2026, he exercised restricted stock units to acquire 5,792 shares of Class A Common Stock, while 2,947 shares were disposed of in a tax-withholding transaction at $3.01 per share. After these transactions, he directly holds 8,580 shares of Class A Common Stock and 57,925 restricted stock units, each representing a contingent right to one share. The RSU award vests in twelve quarterly installments beginning April 15, 2026, subject to his continued service.
GoodRx Holdings, Inc. reported the results of its annual stockholder meeting held on June 16, 2026. Class A stockholders had one vote per share and Class B stockholders had ten votes per share as of the April 20, 2026 record date.
A total of 89,932,951 Class A shares and 233,964,187 Class B shares were represented, accounting for approximately 99.4% of the combined voting power. Stockholders elected Wendy Barnes, Ronald E. Bruehlman and Gregory Mondre as Class III directors.
They also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory and non-binding basis, the compensation of the company’s named executive officers.
REY-GIRAUD AGNES reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Agnes Rey-Giraud reported an equity compensation grant in the form of restricted stock units covering 73,434 shares of Class A common stock. These units were awarded at no cash cost to her and represent a contingent right to receive shares in the future.
The restricted stock units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the company’s 2027 Annual Meeting of Stockholders, assuming she continues her service through that date. Following this grant, she holds 426,286 shares of Class A common stock directly, reflecting a routine director compensation award rather than an open-market purchase.
Kennedy Kelly J. reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings director Kelly J. Kennedy received an equity award of 73,434 restricted stock units (RSUs) of Class A common stock. The RSUs were granted at no cash cost and each unit represents a right to one share. They vest in full on the earlier of the one-year anniversary of June 16, 2026 or the 2027 Annual Meeting of Stockholders, subject to continued service. Following this grant, Kennedy holds 207,645 Class A shares/units directly.
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Douglas Joseph Hirsch reported an equity compensation grant on Class A common stock. He received 73,434 deferred stock units, each representing a right to one share at no cash cost. These units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the company’s 2027 annual stockholders’ meeting, subject to his continued service.
The deferred stock units will be settled in shares upon the earliest of December 31, 2029, separation from service, a change in control, death, or disability under the company’s director deferred compensation plan. After this grant, Hirsch directly holds 320,936 Class A shares. Additional Class A shares are held indirectly through grantor retained annuity trusts and by his spouse; certain CH GRAT holdings are attributed to those trusts and his spouse, and he disclaims beneficial ownership of those particular shares.
Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Ronald E. Bruehlman received an equity grant of 73,434 deferred stock units representing Class A common stock. These units are granted at no cash cost and increase his direct holdings to 207,352 shares after the award.
Each deferred stock unit gives the right to receive one Class A share. The units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service. Settlement into shares occurs on the earliest of December 31, 2031, a separation from service, a change in control, death, or disability, as defined under the company’s Deferred Compensation Plan for Directors.
Bezdek Trevor reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings director Trevor Bezdek reported a compensation grant of 73,434 restricted stock units (RSUs), each representing one share of Class A common stock at a stated price of $0.00 per share. These RSUs vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service. Following this award, he holds 343,810 Class A shares directly and has additional indirect interests through TB 2024-2 GRAT and TB 2025 GRAT. Separate JB 2024-2 GRAT and JB 2025 GRAT positions, as well as one share held by his spouse, are associated with his spouse, and he disclaims beneficial ownership of those shares.